Deinove takes a step forward in the industrialization of its carotenoid production process. The French biotech company discovers, develops, and produces high-value compounds from rare bacteria, notably from the Deinococcus genus.
In November 2016, the company led by Emmanuel Periot launched the shift from laboratory to industrial scale. This phase I has been conducted successfully. A first molecule has been selected for its innovative feature, with the goal of obtaining a competitive advantage on the market. Deinove has demonstrated its total safety, but also its antioxidant and healing properties, which position this first molecule as particularly favorable for cosmetic applications. The carotenoid-producing strain was optimized and tested in fermenters of up to 20 liters. The yields obtained were significantly higher than the target yields, ensuring the economic viability of the production process. The work carried out with the company Processium led to the evaluation of various extraction and purification techniques available on the market.
It is now necessary to validate the performance of these techniques in order to prepare the transition to the industrial scale. The first laboratory-scale tests yielded an extract with a purity level suited for an actual commercialization.
The quality of the results obtained makes it possible to start phase II of this program, which aims to validate all the technical conditions and to select the subcontractors best suited for production at an industrial scale. This phase II should continue until the end of 2017 and lead to the production of the first batches of this carotenoid.
“Our Carotenoids program – Marie Bezenger, director of Operations for Deinove, said – confirms its industrial potential: we have achieved particularly promising performances, exceeding our expectations. We are now working on accelerating the production of the first carotenoid batches.”
“We are moving forward – Emmanuel Petiot, Ceo of the French company added – with the goal of bringing our first molecule to market during 2018. In parallel with the development of the program, we are actively preparing this commercial launch by thoroughly working on marketing and setting up contacts with several potential industrial customers, mainly in the field of cosmetics, which seem perfectly adapted to kick-off the commercialization of this molecule.”